Icon (ICLR) Gets a Buy from Leerink Partners
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Cherny is a 4-star analyst with an average return of 4.7% and a 54.30% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Cardinal Health, and CVS Health.
In addition to Leerink Partners, Icon also received a Buy from Truist Financial's Jailendra Singh in a report issued on July 9. However, on June 25, Barclays maintained a Hold rating on Icon (NASDAQ: ICLR).
ICLR market cap is currently $12.28B and has a P/E ratio of 16.38.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICLR in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
S&P/TSX composite edges higher in late-morning trading
TORONTO — Canada's main stock index edged higher in late-morning trading as strength in the industrial sector battled weakness in technology and base metal stocks. The S&P/TSX composite index was up 2.03 points at 27,924.88. In New York, the Dow Jones industrial average was up 74.32 points at 44,986.14. The S&P 500 index was down 22.59 points at 6,426.56, while the Nasdaq composite was down 225.40 points at 21,404.37. The Canadian dollar traded for 72.19 cents US compared with 72.42 cents US on Monday. The October crude oil contract was down 64 cents US at US$62.06 per barrel. The December gold contract was down US$11.90 at US$3,366.10 an ounce. This report by The Canadian Press was first published Aug. 19, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Defiance ETFs Launches Leveraged + Income ETFs for Palantir (PLT), Hims & Hers Health (HIMY), and Robinhood Markets (HOOI)
Defiance ETFs Launches Leveraged + Income ETFs for Palantir (PLT), Hims & Hers Health (HIMY), and Robinhood Markets (HOOI) MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leading innovator in thematic and leveraged exchange-traded funds, today announced the launch of three new single-stock leveraged ETFs with income strategies: Defiance Leveraged Long + Income PLTR ETF (NASDAQ: PLT) – providing leveraged exposure to Palantir Technologies. Invest in Gold Thor Metals Group: Best Overall Gold IRA American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Defiance Leveraged Long + Income HIMS ETF (NASDAQ: HIMY) – providing leveraged exposure to Hims & Hers Health. Defiance Leveraged Long + Income HOOD ETF (NASDAQ: HOOI) – providing leveraged exposure to Robinhood Markets. Each ETF combines approximately 150%–200% leveraged exposure to its underlying stock with an options-based credit call spread income strategy, designed to offer investors amplified growth potential and consistent cash flow. What Sets These Funds Apart Leveraged Exposure: Each fund seeks to deliver approximately 150% to 200% of its underlying stock's daily price performance. Income Generation: The options-driven income overlay aims to generate premium income and provide a potential buffer against declines. Accessible Structure: Investors gain targeted, amplified exposure without needing a margin account. Why These Companies? Palantir Technologies: A leader in AI-driven data analytics, providing platforms such as Foundry and Gotham to governments and enterprises worldwide. Hims & Hers Health: A pioneer in personalized telehealth and direct-to-consumer healthcare, redefining access to wellness and treatment. Robinhood Markets: A disruptor in retail investing, expanding access to commission‑free trading and broader financial markets. Investment ObjectivesEach ETF seeks long-term capital appreciation as its primary objective, with a secondary objective of current income. The leveraged strategy provides amplified exposure to the underlying stock, while the income strategy uses credit call spreads to generate premium income and manage risk associated with DefianceFounded in 2018, Defiance is at the forefront of ETF innovation. The firm specializes in thematic, income, and leveraged ETFs, including first-mover leveraged single-stock products that empower investors to take amplified positions in high‑growth companies. IMPORTANT DISCLOSURESThe Funds' investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read carefully before investing. A hard copy of the prospectuses can be requested by calling 833.333.9383. Defiance ETFs LLC is the ETF sponsor. The Funds' investment adviser is Tidal Investments, LLC ('Tidal' or the 'Adviser'). Investing involves risk. Principal loss is possible. An investment in any Fund is not an investment in its underlying company (Palantir Technologies, Hims & Hers Health, or Robinhood Markets). PLT Risks. The Fund invests in swap contracts and options that are based on the share price of Palantir Technologies ('PLTR'). If the share price of PLTR decreases, the Fund will likely lose value and may suffer significant losses. Indirect Investment in PLTR Risk: PLTR is not affiliated with the Trust, the Fund, the Adviser or their affiliates and is not involved with this offering. Investors in the Fund will not have voting rights in PLTR but will be exposed to its performance. PLTR Trading Risk: The trading price of PLTR may be highly volatile and subject to wide fluctuations. PLTR Performance Risk: PLTR may fail to meet publicly announced guidelines or other expectations, which could cause its share price to decline. Software and Data Analytics Industry Risk: Companies in this industry can be significantly affected by competition, technological change, intellectual property disputes, evolving customer demands, and cybersecurity threats. Government Contract Risk: A significant portion of PLTR's revenue is derived from contracts with government agencies that may be modified, delayed, not renewed, or terminated. HIMY Risks. The Fund invests in swap contracts and options that are based on the share price of Hims & Hers Health ('HIMS'). If the share price of HIMS decreases, the Fund will likely lose value and may suffer significant losses. Indirect Investment in HIMS Risk: HIMS is not affiliated with the Trust, the Fund, the Adviser or their affiliates and is not involved with this offering. Investors in the Fund will not have voting rights in HIMS but will be exposed to its performance. HIMS Trading Risk: The trading price of HIMS may be highly volatile and subject to wide fluctuations. HIMS Performance Risk: HIMS may fail to meet publicly announced guidelines or other expectations, which could cause its share price to decline. Telehealth and Consumer Healthcare Industry Risk: Companies in this industry are subject to risks including regulatory changes, evolving healthcare policies, competition, technological disruption, supply chain issues, and changes in consumer preferences. Regulatory and Compliance Risk: HIMS operates in a highly regulated healthcare environment; changes in telehealth regulations, privacy laws, or prescription requirements could materially impact operations and revenue. HOOI Risks. The Fund invests in swap contracts and options that are based on the share price of Robinhood Markets ('HOOD'). If the share price of HOOD decreases, the Fund will likely lose value and may suffer significant losses. Indirect Investment in HOOD Risk: HOOD is not affiliated with the Trust, the Fund, the Adviser or their affiliates and is not involved with this offering. Investors in the Fund will not have voting rights in HOOD but will be exposed to its performance. HOOD Trading Risk: The trading price of HOOD may be highly volatile and subject to wide fluctuations. HOOD Performance Risk: HOOD may fail to meet publicly announced guidelines or other expectations, which could cause its share price to decline. Brokerage and Financial Services Industry Risk: Companies in this industry are subject to extensive regulation, competition, technological change, cybersecurity threats, and market conditions that affect profitability. Changes in interest rates, customer trading volumes, and investor sentiment can directly impact financial performance. Regulatory Risk: Brokerage and trading platform operators are subject to ongoing oversight from multiple regulatory agencies; changes in regulations, enforcement actions, or legal proceedings could adversely impact HOOD's business model and revenues. Additional Risks. Derivatives Risks: Derivative investments can exhibit imperfect correlation to the underlying assets or index and may result in losses greater than the initial investment. Leverage Risk: Swap contracts and options create additional investment exposure to the underlying securities and increase the potential for loss. Compounding and Market Volatility Risk: Over periods longer than a single trading day, compounding may cause performance to differ from the stated leverage target range. High Portfolio Turnover Risk: A high portfolio turnover rate increases transaction costs, which may raise expenses and reduce performance. Non-Diversification Risk: Because the Funds are non-diversified, they may invest a greater percentage of assets in a single issuer or a smaller number of issuers. New Fund Risk: As newly formed funds, they have no operating history, providing limited basis for investors to assess performance or management. Brokerage commissions may be charged on trades. Distributed by Foreside Fund Services, LLC. Contact: David Hanono info@ | 833.333.9383 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
Waldencast PLC (WALD) Q2 2025 Earnings Report Preview: What To Look For
Waldencast PLC (NASDAQ:WALD) is set to release its Q2 2025 earnings on Aug 19, 2025. The consensus estimate for Q2 2025 revenue is $68.11 million, and the earnings are expected to come in at -$0.04 per share. The full year 2025's revenue is expected to be $308.95 million, and the earnings are expected to be -$0.33 per share. More detailed estimate data can be found on the Forecast page. Waldencast PLC (NASDAQ:WALD) Estimate Trends Warning! GuruFocus has detected 3 Warning Signs with WALD. Over the past 90 days, revenue estimates for Waldencast PLC (NASDAQ:WALD) have increased from $308.19 million to $308.95 million for the full year 2025 and from $357.01 million to $357.81 million for 2026. Conversely, earnings estimates have declined from -$0.31 per share to -$0.33 per share for the full year 2025 and remained flat at -$0.26 per share for 2026. Waldencast PLC (NASDAQ:WALD) Reported History In the previous quarter ending on December 31, 2024, Waldencast PLC's (NASDAQ:WALD) actual revenue was $72.10 million, which beat analysts' revenue expectations of $70.65 million by 2.06%. Waldencast PLC's (NASDAQ:WALD) actual earnings were -$0.18 per share, which missed analysts' earnings expectations of -$0.05 per share by -246.15%. After releasing the results, Waldencast PLC (NASDAQ:WALD) was up by 3.61% in one day. Waldencast PLC (NASDAQ:WALD) 12 Month Price Targets Based on the one-year price targets offered by 5 analysts, the average target price for Waldencast PLC (NASDAQ:WALD) is $3.98, with a high estimate of $5.00 and a low estimate of $2.40. The average target implies an upside of 130.06% from the current price of $1.73. Based on GuruFocus estimates, the estimated GF Value for Waldencast PLC (NASDAQ:WALD) in one year is $0, suggesting a downside of -100% from the current price of $1.73. Based on the consensus recommendation from 6 brokerage firms, Waldencast PLC's (NASDAQ:WALD) average brokerage recommendation is currently 2.2, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.
